Profile data is unavailable for this security.
About the company
LifeVantage Corporation is engaged in the identification, research, development, formulation and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. The Company's dietary supplements include its flagship Protandim family of products, LifeVantage Omega+, ProBio, IC Bright, and Daily Wellness dietary supplements. The Protandim product line includes Protandim NRF1 Synergizer, Protandim Nrf2 Synergizer, and Protandim NAD Synergizer. TrueScience is its line of skin, hair, bath and body, and targeted relief products. The Company also markets and sells Petandim, its companion pet supplement formulated to combat oxidative stress in dogs; Axio, its nootropic energy drink mixes, and PhysIQ, its smartweight management system, which includes PhysIQ Fat Burn and PhysIQ Prebiotic, all formulated to aid in weight management.
- Revenue in USD (TTM)205.45m
- Net income in USD3.60m
- Incorporated2018
- Employees248.00
- LocationLifeVantage Corp3300 TRIUMPH BLVD, SUITE 700LEHI 84043United StatesUSA
- Phone+1 (801) 432-9000
- Fax+1 (302) 636-5454
- Websitehttps://www.lifevantage.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eagle Pharmaceuticals Inc | 257.55m | 11.95m | 69.87m | 134.00 | 5.91 | 0.2795 | 2.14 | 0.2713 | 0.911 | 0.911 | 19.59 | 19.25 | 0.6549 | 1.55 | 2.56 | 1,922,022.00 | 3.04 | 6.37 | 4.04 | 7.98 | 69.84 | 71.86 | 4.64 | 7.85 | 1.67 | 3.55 | 0.2178 | 0.00 | 84.56 | 5.99 | 513.14 | -8.42 | -49.05 | -- |
| CEL-SCI Corp | 0.00 | -29.95m | 73.12m | 43.00 | -- | 5.10 | -- | -- | -0.6304 | -0.6304 | 0.00 | 0.2645 | 0.00 | -- | -- | -- | -87.78 | -70.19 | -103.56 | -78.31 | -- | -- | -- | -15,434.15 | 1.18 | -39.26 | 0.4319 | -- | -- | -- | 13.99 | -- | 223.59 | -- |
| Journey Medical Corp | 80.00m | -4.16m | 75.67m | 58.00 | -- | 8.31 | -- | 0.9459 | -0.3095 | -0.3095 | 4.13 | 0.6498 | 0.985 | 2.27 | 4.28 | 1,379,276.00 | -5.12 | -- | -17.85 | -- | 66.22 | -- | -5.20 | -- | 0.9357 | 0.4049 | 0.5773 | -- | 7.48 | -- | 87.00 | -- | -- | -- |
| SCYNEXIS Inc | 140.39m | 101.33m | 76.32m | 29.00 | 1.00 | 1.03 | -- | 0.5436 | 2.01 | 2.01 | 2.89 | 1.96 | 1.49 | -- | 136.30 | 4,840,862.00 | 107.48 | -30.02 | 175.37 | -36.35 | 88.97 | -- | 72.18 | -86.76 | -- | 193.81 | 0.1433 | -- | 2,652.72 | 252.64 | 206.74 | -- | -- | -- |
| Eyenovia Inc | 8.78k | -32.44m | 77.50m | 57.00 | -- | 36.76 | -- | 8,826.49 | -0.7448 | -0.7448 | 0.0002 | 0.0384 | 0.0003 | -- | 0.008 | 154.04 | -116.94 | -80.31 | -190.14 | -117.70 | 0.00 | -- | -369,519.70 | -680.95 | 0.6645 | -16.03 | 0.8914 | -- | -- | -- | 2.68 | -- | 152.20 | -- |
| Marinus Pharmaceuticals Inc | 28.29m | -145.34m | 77.73m | 165.00 | -- | -- | -- | 2.75 | -2.64 | -2.64 | 0.5142 | -0.2992 | 0.1554 | 0.8536 | 3.72 | 171,442.40 | -79.82 | -49.64 | -96.93 | -57.76 | 91.22 | -- | -513.80 | -518.96 | 2.93 | -13.62 | 1.29 | -- | 21.63 | -- | -613.59 | -- | 7.47 | -- |
| Cellectar Biosciences Inc | 0.00 | -50.98m | 83.71m | 20.00 | -- | 8.52 | -- | -- | -3.17 | -3.17 | 0.00 | 0.789 | 0.00 | -- | -- | 0.00 | -176.58 | -83.69 | -295.36 | -99.80 | -- | -- | -- | -- | -- | -4.81 | 0.00 | -- | -- | -- | -32.80 | -- | 17.55 | -- |
| CASI Pharmaceuticals Inc | 28.94m | -30.48m | 87.11m | 176.00 | -- | 5.63 | -- | 3.01 | -2.28 | -2.28 | 2.16 | 1.15 | 0.3954 | 1.00 | 3.41 | 164,437.50 | -40.88 | -34.75 | -59.15 | -46.91 | 58.36 | 55.98 | -103.40 | -153.72 | 3.25 | -76.70 | 0.5458 | -- | -21.41 | -- | 34.27 | -- | 14.65 | -- |
| LifeVantage Corp | 205.45m | 3.60m | 88.01m | 248.00 | 24.79 | 3.28 | 12.10 | 0.4284 | 0.2796 | 0.2796 | 16.01 | 2.11 | 3.20 | 2.53 | 91.56 | 828,443.60 | 5.60 | 11.65 | 8.51 | 18.92 | 79.32 | 82.20 | 1.75 | 3.42 | 1.01 | -- | 0.00 | 5.23 | 3.41 | 0.9838 | -18.59 | -18.77 | -7.98 | -- |
| Zhong Yuan Bio-Technology Holdings Ltd | 2.49m | 232.02k | 88.22m | 35.00 | 391.37 | 348.44 | -- | 35.38 | 0.0128 | -0.0176 | 0.1395 | 0.0143 | 0.8583 | -1.61 | 3.25 | 71,253.43 | 6.49 | -- | 19.10 | -- | 106.30 | -- | 7.57 | -- | 0.8309 | 2.53 | 0.8593 | -- | -28.60 | -- | -148.37 | -- | -- | -- |
| Eton Pharmaceuticals Inc | 34.30m | 913.00k | 91.20m | 30.00 | 104.94 | 5.89 | 49.22 | 2.66 | 0.0338 | 0.0338 | 1.33 | 0.6031 | 1.25 | 8.41 | 9.64 | 1,143,467.00 | 3.34 | -46.22 | 5.72 | -58.20 | 66.24 | 72.16 | 2.66 | -76.86 | 1.43 | -- | 0.2447 | -- | 48.90 | -- | 89.62 | -- | 26.85 | -- |
| Elutia Inc | 25.05m | -49.46m | 92.77m | 54.00 | -- | -- | -- | 3.70 | -2.35 | -2.34 | 1.24 | -2.07 | 0.5219 | 2.06 | 4.27 | 463,833.30 | -103.05 | -42.93 | -599.50 | -79.34 | 42.01 | 43.32 | -197.48 | -64.16 | 0.5499 | -1.36 | -- | -- | -49.69 | -8.71 | -25.39 | -- | 12.74 | -- |
Data as of Jul 25 2024. Currency figures normalised to LifeVantage Corp's reporting currency: US Dollar USD
24.78%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Renaissance Technologies LLCas of 31 Mar 2024 | 837.82k | 6.60% |
| Sudbury Capital Management LLCas of 26 Feb 2024 | 749.33k | 5.90% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 471.99k | 3.72% |
| Dimensional Fund Advisors LPas of 31 Mar 2024 | 280.35k | 2.21% |
| Acadian Asset Management LLCas of 31 Mar 2024 | 228.09k | 1.80% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 201.85k | 1.59% |
| Geode Capital Management LLCas of 31 Mar 2024 | 123.83k | 0.98% |
| Bridgeway Capital Management LLCas of 31 Mar 2024 | 102.10k | 0.80% |
| Empowered Funds LLCas of 31 Mar 2024 | 76.20k | 0.60% |
| Perkins Capital Management, Inc.as of 31 Mar 2024 | 76.11k | 0.60% |
More ▼
Data from 31 Mar 2024 - 01 Jul 2024Source: FactSet Research Systems Inc.
